Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Other Operating Expenses (2018 - 2023)

Historic Other Operating Expenses for Exagen (XGN) over the last 6 years, with Q4 2023 value amounting to -$17.5 million.

  • Exagen's Other Operating Expenses fell 24787.98% to -$17.5 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$17.5 million, marking a year-over-year decrease of 15965.79%. This contributed to the annual value of $29.7 million for FY2022, which is 4435.59% up from last year.
  • According to the latest figures from Q4 2023, Exagen's Other Operating Expenses is -$17.5 million, which was down 24787.98% from $5.7 million recorded in Q3 2023.
  • Over the past 5 years, Exagen's Other Operating Expenses peaked at $11.8 million during Q4 2022, and registered a low of -$17.5 million during Q4 2023.
  • For the 5-year period, Exagen's Other Operating Expenses averaged around $4.3 million, with its median value being $5.0 million (2019).
  • In the last 5 years, Exagen's Other Operating Expenses surged by 13921.85% in 2022 and then crashed by 24787.98% in 2023.
  • Over the past 5 years, Exagen's Other Operating Expenses (Quarter) stood at $4.6 million in 2019, then decreased by 5.58% to $4.3 million in 2020, then increased by 13.93% to $4.9 million in 2021, then skyrocketed by 139.22% to $11.8 million in 2022, then crashed by 247.88% to -$17.5 million in 2023.
  • Its Other Operating Expenses was -$17.5 million in Q4 2023, compared to $5.7 million in Q3 2023 and $5.8 million in Q2 2023.